[go: up one dir, main page]

WO1998008535A2 - Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 - Google Patents

Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 Download PDF

Info

Publication number
WO1998008535A2
WO1998008535A2 PCT/US1997/015016 US9715016W WO9808535A2 WO 1998008535 A2 WO1998008535 A2 WO 1998008535A2 US 9715016 W US9715016 W US 9715016W WO 9808535 A2 WO9808535 A2 WO 9808535A2
Authority
WO
WIPO (PCT)
Prior art keywords
lectin
cells
tumor
lectins
human
Prior art date
Application number
PCT/US1997/015016
Other languages
English (en)
Other versions
WO1998008535A3 (fr
Inventor
Linda G. Baum
Nancy L. Perillo
Jeffrey J. Seilhamer
Original Assignee
Incyte Pharmaceuticals, Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals, Inc., The Regents Of The University Of California filed Critical Incyte Pharmaceuticals, Inc.
Priority to AU40913/97A priority Critical patent/AU4091397A/en
Publication of WO1998008535A2 publication Critical patent/WO1998008535A2/fr
Publication of WO1998008535A3 publication Critical patent/WO1998008535A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the invention relates to the use of carbohydrate-binding proteins as regulators of cell differentiation and immunity.
  • it concerns a pharmaceutical composition where the active ingredient is a soluble lectin of about 14 kD or a fragment thereof which can be isolated from human HL-60 cells or placenta tissue.
  • Recombinant materials and methods to produce these inventive lectins are also provided.
  • This invention is also directed to methods to treat autoimmune diseases, certain neoplastic diseases characterized by the proliferation of lymphocytes and to prevent transplant rejection.
  • the invention is directed to methods of treating tumors that produce the inventive lectin.
  • Lectins are defined as proteins which specifically bind carbohydrates of various types. Initial interest was focused on those isolated from plants such as concanavalin A and ricin agglutinin. These lectins, it was found, were useful in protein purification procedures due to the glycosylation state of a number of proteins of interest. Among the soluble lectins, there appear to be a number of varieties with varying molecular weights and or carbohydrate specificities. Sparrow, C.P., et al., J. Biol. Chem. (1987) 252:7383- 7390 describe three classes of soluble lectins from human lung, one of 14 kD, one of 22 kD, and a third of 29 kD.
  • lectins are specific to ⁇ -D-galactosides.
  • the carbohydrate specificities of the 14 kD class are for the most part similar, but the larger molecular weight species tend to have different specificities.
  • Other species are also noted as showing more than one soluble ⁇ -D-galactoside-binding lectin, including mouse (Roff, C.F., et al., J. Biol. Chem. (1983) 258:10637-10663); rat (Cerra. R.F.. et al.. J. Biol. Chem. (1985) 260:10474-10477) and chickens (Beyer, E.C., et al., J. Biol. Chem.
  • lactose-extractable lectins which bind specifically to certain ⁇ -D-galactoside containing moieties and are found in a wide range of mammalian, invertebrate, avian. and even microbial sources. All of the lectins in this class appear to contain subunits with molecular weights of about 12 -18 kD. Furthermore, these lectins can be readily classified by virtue of a simple diagnostic test: their ability to agglutinate trypsin-treated rabbit red blood cells is specifically inhibited by certain ⁇ -D-galactose-containing moieties.
  • the agglutination can be inhibited by, for example, lactose, thiodigalactoside and certain other ⁇ -D-galactose containing moieties.
  • lactose thiodigalactoside
  • ⁇ -D-galactose containing moieties Other common characteristics include no requirement for metal ions in effecting agglutination and the required presence of a reducing agent such as a thiol. Gitt. M.A. et al.. Proc. Natl. Acad. Sci.
  • Acta (1987) 925:290-296 describe the purification and characterization of lectins from rat and bovine brain tissue.
  • deCabutti, N.E.F.. et al., FEBS Letters (1987) 223:330-334 describe a lectin from amphibian ovary.
  • the isolation from eel of a similar "electrolectin” had previously been described by Levi. G., et al., J. Biol. Chem. (1981) 256:5735-5740.
  • An additional analogous 14 kD lectin was produced by cloning and expression of cDNA derived from various murine fibrosarcoma cell lines by Raz, A., et al..
  • Paroutaud, P., et al.,(Proc. Natl. Acad. Sci. USA ( 1987) 84:6345-6348) compared the amino acid sequences of several animal lectins including those from chick, eel, human placenta, human lung, and two hepatoma-derived lectins (all of these lectins described as referenced above). Only the chicken lectin contains an "N-linked" glycosylation site, which is not conjugated to saccharide. No known mammalian lectin in this family has an N-linked glycosylation site.
  • the preferred lectins of the present invention are isolated from the human promyelocytic leukemia cell line HL-60 or human placenta tissue. Lectins have been isolated from the HL-60 cell line by others, but they are markedly different from the lectins of the present invention. Paietta, E.. et al.. Cancer Res. (1988) 48:280-287 describe a membrane-bound (not soluble), 17 kd lectin which recognizes N-acetyl neuraminic acid as well as galactose terminating biantennary oligosaccharide structures.
  • this 17 kd lectin is not inhibited by complex galactose saccharides such as thiodigalactoside and does not require reducing thiol groups for binding activity.
  • complex galactose saccharides such as thiodigalactoside
  • ligand specificity and biodistribution of the lectin protein described herein are an abrupt departure from the earlier disclosed lectins. Because the activities of lectins in regulating the immune system and mediating other forms of intercellular communication are so subtle in nature and so critically tuned to the host environment, subtle changes in structure can result in a wide range of such regulators with differing therapeutic and diagnostic uses.
  • lectins As described above, a number of members of the class of ⁇ -D-galactose-binding soluble lectins weighing approximately 14 kD are known in the art. However, while these lectins have some similarities, they are not interchangeable therapeutically or diagnostically. In addition, it appears that for lectins which can be glycosylated, the extent and nature of the glycosylation can be manipulated to alter important lectin properties (e.g., circulating half-life, metabolism in vivo, solubility, stability, and specific activity).
  • the inventive lectin is now recognized as a member of the galectin family, a family of thiol-dependent, ⁇ -galactoside binding molecules highly conserved across species ranging from sponges to humans and is also known as galectin- 1 .
  • galectin- 1 Barondes. S.H.. et al Cell 76:597-598 (1994); Hirabayashi. J. & Kasai, K-i, Glycobiology 3:297-304 ( 1993); Barondes, S.H., Cooper, D.N.W., Gitt, M.A. & Leffler, H. J. Biol. Chem. 269:20807-
  • the inventive lectin is a soluble homodimer of 14.5 kilodalton subunits, found in a number of tissues. (Barondes. S.H.. Cooper. D.N.W., Gitt, M.A. & Leffler, H. J Diol. Chem. 269:20807-20810 ( 1994)). While the crystal structure and oligosaccharide binding specificity of the lectin have been well characterized (Hughes, R.C. Curt: Opin. Struct. Biol.
  • the inventive lectin exists as a homodimer at concentrations greater than 7 ⁇ M. (Cho, M. & Cummings, R.D. J. Biol. Chem. 270:5207-5212 (1995)). Dimeric lectin remains cell-surface associated (Baum, L.G., Pang, M., Perillo, N.L., Wu, T. & Seilhamer, j.j. J. Exp. Med. 181:877-887 (1995); Cho, M. & Cummings, R.D. J. Biol. Chem. 270:5207-5212 (1995)) and has been proposed to bridge opposing glycoproteins. (Cooper D.N.W., Massa, S.M.
  • the reported synthesis of the inventive lectin by epithelial tumors may have immunosuppressive effects on tumor infiltrating T lymphocytes, thus enabling tumor cells to evade immune surveillance.
  • Prominent diseases in which there is an immune system dysfunction include autoimmune diseases such as myasthenia gravis (MG), rheumatoid arthritis (RA) systemic lupus erythematosus (SLE). multiple sclerosis (MS) and juvenile arthritis.
  • MG, RA, SLE and MS are treated first with corticosteroids.
  • Steroidal drugs have been used for decades and their adverse effects are well known.
  • Adverse effects that can be anticipated in all patients on prolonged steroid therapy include osteoporosis, truncal obesity, impaired wound healing, infections and growth arrest in children.
  • Less frequently occurring adverse effects include myopathy, hypertension, hyperlipidemia, diabetes mellitus and cataracts. Severe side effects may develop and require patient monitoring. These include glaucoma, intracranial hypertension, intestinal perforation, and ulcers.
  • MG, RA, SLE or MS become refractory to steroids, then increasingly toxic drugs are employed, including azathioprine, methotrexate and cyclophosphamide.
  • azathioprine inhibits DNA synthesis, thus lowering numbers of T and B lymphocytes.
  • azathioprine inhibits the mixed lymphocyte reaction and immunoglobulin production, but does not consistently affect delayed-type hypersensitivity.
  • the major adverse effect of azathioprine is pancytopenia, particularly lymphopenia and granulocytopenia. Consequently, there are increased risks of viral, fungal, mycobacterial and protozoal infections. An increased rate of lymphoreticular malignancies has been reported in kidney transplant patients, but not in patients with RA.
  • Methotrexate inhibits folic acid synthesis and is cytotoxic. suppressing bone marrow. At the low doses used for RA, methotrexate should not decrease the numbers of lymphocytes; but IgM and IgG are reduced. Side effects include pneumonia, nausea, stomach upsets, mouth ulcers, leukopenia, thrombocytopenia. and a form of hepatic fibrosis. which can only be diagnosed by liver biopsy.
  • Cyclophosphamide is also used in RA therapy. It is metabolized in the liver to a compound which cross-links DNA. Cyclophosphamide is cytotoxic, with severe toxicity seen even at low doses. It affects RA by reducing numbers of B- and T-lymphocytes, decreasing the immunoglobulin concentrations and diminishing B-cell responsiveness to mitogenic stimuli. Hair loss, infections, and powerful nausea are common. With prolonged administration, patients develop malignancies at an increased rate.
  • Cyclosporin does not suppress white cells, but it is a powerful immunomodulatory drug and is effective in treating rheumatoid arthritis. However, an important side effect is renal toxicity.
  • RA RA-associated antimalarials
  • sulfasalazine and penicillamine Other drugs have been used specifically in RA, including gold salts, antimalarials. sulfasalazine and penicillamine. Gold salts are given intramuscularly and their effect may not be seen for months. Adverse effects of gold treatment include bone marrow aplasia, glomerulonephritis, pulmonary toxicity, vasomotor reactions and inflammatory flare. Antimalarials exert several effects on the immune system without decreasing the numbers of lymphocytes. The most serious side effects of antimalarials include retinal pigment deposition, rash and gastrointestinal upset. Sulfasalazine has several effects which contribute to its effect on RA; however, it has numerous side effects.
  • Penicillamine has been successfully used in RA; however, its numerous side effects have limited its use. Penicillamine has been reported to cause other autoimmune diseases, including myasthenia gravis and SLE. When patients receive allografts (transplanted tissue from other humans or other sources), their immune systems can destroy the allografts in short order were it not for the administration of immunosuppressant drugs. A number of different organs and tissues are now transplanted, including the kidneys, heart, lungs, skin, bone marrow, cornea, and liver. Drugs frequently used in transplant patients include cyclosporin, azathioprine. rapamycin. other macrolides such as FK506, prednisone.
  • methylprednisolone CD4 antibodies and cyclophosphamide.
  • these drugs must be given in higher doses and for longer periods to transplant patients than to patients with autoimmune diseases.
  • side effects from these drugs may be more common and severe in transplant patients.
  • What was needed before the present invention is a drug that would selectively treat autoimmune diseases, neoplastic diseases characterized by the proliferation of lymphocytes, lectin-producing tumors and transplant rejection without the severe side effects of the previously known therapies.
  • the present invention is directed to a pharmaceutical composition.
  • the active agent is a soluble lectin of MW of about 14 kD or a fragment thereof, wherein the lectin or fragment (1 ) binds ⁇ -galactoside-containing moieties whether Ca + 2 j s present or not, (2) stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays which is inhibited by lactose or thiodigalactoside, (3) provides an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of Figure 1 or the relevant portions thereof, and wherein the active ingredient is mixed with a carbohydrate and at least one pharmaceutically acceptable excipient.
  • the composition can also contain one or more general immune system suppressants such as cyclosporin.
  • the invention also provides recombinant materials and methods to produce these new lectins.
  • the invention is directed to methods to treat autoimmune diseases and neoplastic diseases characterized by the proliferation of lymphocytes and to prevent transplant rejection. The efficacy of these methods results from the surprising ability of the inventive lectin to react with activated T cells causing apoptosis of the cells and thereby suppress the host immune response to both autoimmunogens and foreign tissue.
  • the invention is directed to methods of treating lectin-producing tumors by the administration of antibodies that specifically bind the inventive lectin. lectin antagonists, inhibitory saccharides and glycosylation inhibitors, thereby preventing lectin-induced apoptosis of tumor-infiltrating T cells.
  • Figure 1 shows the cDNA sequence and deduced amino acid sequence of both the HL-60 and placenta lectin. Superscript numbers correlate to the corresponding nucleotides and boxes show start and stop codons. The asterisk indicates the possible N-linked glycosylation site.
  • Figure 2 shows immunostaining of thymic epithelium by anti-lectin and anti- cytokeratin antibodies.
  • Figure 3 shows an electrophoresis gel with staining in a location indicative of mRNA for the inventive lectin in thymic epithelial cells.
  • Figure 4 shows the percentage of ARR T-cells that adhered to thymic epithelial cells with and without enzyme treatment.
  • Figure 5 shows results of hemagglutinin bioassay of purified lectins from human placenta, HL-60 cells and E. coli cells transfected with vectors containing lectin cDNA and an operably linked secretion signal, and inhibition of agglutination by sugars.
  • Figure 6 shows the effect of several doses of the inventive lectin on the primary immune response to tetanus toxoid.
  • Figure 7 shows the effect of several doses of the inventive lectin on the primary immune response to pneumococcal polysaccharide.
  • Figure 8 shows the effect of several doses of the inventive lectin on the primary immune response against the Torpedo receptor.
  • Figure 9 shows the effect of several doses of the inventive lectin on the primary immune response against mouse skeletal muscle receptor in animals immunized with the Torpedo receptor.
  • Figures 10 and 1 1 show the results of the treatment with the inventive lectin on clinical symptoms in a rat model for multiple sclerosis.
  • Figure 12 is a graphical representation of the effect of recombinantly produced lectin in a rat model for multiple sclerosis.
  • Figure 13 shows the effect of the recombinantly produced lectin on a relapse murine model for multiple sclerosis.
  • Figure 14 is a graphical comparison of the survival of skin allografts when rats received lectin and placebo.
  • Figures 15 A-F illustrate lectin induction of apoptosis of T cells via carbohydrate- specific interactions.
  • Figures 15A and 15B show that lectin treatment of day 5 PHA blasts induced DNA fragmentation detected as an increase in the percent of cells with hypodiploid DNA content in lectin-treated cells (B) relative to untreated cells (A).
  • Figures 15C and 15D show that lectin also induced DNA fragmentation of MOLT-4 T lymphoblastoid cells as detected by hypodiploid DNA content (not shown) and by in situ nick end-labeling.
  • Figure 15E shows that apoptosis was reversed by the addition of lactose up to 10 minutes after exposure to lectin.
  • Figure 15F shows that 10 ⁇ M of lectin was necessary to induce apoptosis. suggesting a requirement for the dimeric form of the lectin.
  • Figures 16A-E show that human endothelial cells expressing the inventive lectin induce apoptosis of T lymphoblastoid cells.
  • Human aortic endothelial cells HAECs
  • MM-LDL minimally oxidized LDL
  • Figure 16A shows that the percentage of apoptotic T cells (unshaded bars) bound to the endothelial cells was increased when the endothelial cells were treated with MM-LDL which increases cell surface expression of lectin.
  • the percentage of apoptotic T cells in wells without HAECs black bars was approximately 5% in all samples.
  • Figure 16B shows that MOLT-4 cells adhere to a HAEC monolayer and undergo apoptosis. Large arrows indicate apoptotic cells stained by in situ nick end-labeling. Small arrows indicate non-apoptotic MOLT-4 cells.
  • Figures 16C -E show both resting and activated T cells bound lectin, but only activated T cells underwent apoptosis in response to lectin. Five human T lymphocytic leukemia cell lines, ARR, MOLT-4, HSB, CEM and Jurkat, tested bound comparable levels of the inventive lectin. Figure 16E shows that of the cell lines tested, ARR, MOLT-4 and HSB were susceptible to lectin-induced apoptosis. whereas CEM and Jurkat were not
  • Figures 17A-B show that CD45 participates in lectin-mediated apoptosis.
  • Figure 17A shows that antibodies to CD43 and CD45 inhibited lectin binding to MOLT-4 cells.
  • Figure 17B shows that lectin-mediated apoptosis of HPB cells requires expression of CD45. 35% of wild type HPB- ALL cells underwent apoptosis in response to lectin. In contrast, lectin did not induce apoptosis of the CD45 negative variant.
  • FIG 18 shows that susceptibility of activated T cells to lectin was altered by pre- incubation with inhibitors of glycosylation.
  • Swainsonine (SW) inhibits mannosidase II and N-linked oligosaccharide processing.
  • BG Benzyl- ⁇ -GalNAc
  • SW treatment abrogated lectin-induced cell death, while BG treatment potentiated it. Both SW and BG decreased the lactose-inhibitable binding of lectin.
  • the invention is directed to pharmaceutical compositions wherein the active ingredient is a soluble, 14 kD lectin or fragment thereof.
  • the preferred lectin of the invention is isolatable from HL-60 cells as well as from human placental tissue.
  • the lectins of this invention are soluble, capable of binding ⁇ -galactoside-containing moieties independent of the presence or absence of calcium ion, capable of stimulating hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays which can be inhibited by lactose or thiogalactoside, and at least 90% homologous to the relevant portion of positions 2-135 of Figure 1.
  • One embodiment consists essentially of the amino acids shown in Figure 1 numbered from 2-135 which contain at least one tripeptide sequence. Asn-X-Thr or Asn-X-Ser. Preferably, this tripeptide sequence provides a glycosylation site.
  • the N- terminal methionine of the HL-60 lectin appears to be cleaved, and the remaining protein can be acetylated.
  • Various forms of post-translational processing can be expected depending on the cell producing the protein. The processed proteins resulting therefrom are, of course, included within the scope of the invention
  • a preferred embodiment of this invention provides a lectin with at least one glycosylation site, exemplified by Asn-Leu-Thr.
  • the glycosylated tripeptide starts at position 96 of the illustrated HL-60 lectin.
  • the native material at least in part, apparently is not glycosylated at this site; however, when the lectin is appropriately produced in certain recombinant hosts, the site can be glycosylated. Accordingly, the invention provides for glycosylated forms, so long as glycosylation does not destroy activity.
  • the preferred lectins include the peptide comprising positions 2-135 in Figure 1 or the naturally occurring mutants or allelic variations thereof. It is well understood that proteins produced by organisms do not necessarily remain stable in the form studied, but that the genes encoding them are subject to occasional natural mutations and variations that change one or a few amino acids; therefore, the proteins resulting from natural mutation are included in the invention, so long as the mutation does not destroy activity.
  • An allelic mutation changing as many as 15 amino acids is not expected to destroy the activity of the lectin.
  • the allelic mutation would change no more than about 10 amino acids. Most preferably, only about five amino acids would be changed by an allelic mutation.
  • fragments of the lectins typified by that shown in Figure 1.
  • the fragments in order to be included within the scope of the invention, must exhibit the specific properties characterizing the class, i.e., they must be soluble, capable of binding ⁇ -galactoside-containing moieties independent of the presence or absence of calcium ion, capable of stimulating hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays which can be inhibited by lactose or thiogalactoside, and at least 90%) homologous to the relevant portion of positions 2-135 of Figure 1. While a specific minimum fragment length cannot now be identified, it is within ordinary routine experimentation to assay candidate fragments for these activities. It is well understood that only portions or fragments of a particular protein can have the activity of the complete natively produced protein.
  • Deletion of one or several amino acids from either the N- or C- terminus generally does not destroy activity; in addition, internal regions not required to maintain conformation or associated with the active sites can be deleted. Whether or not a protein fragment falls within the scope of the invention is readily determined by means of the assay systems described below for determination of ability to effect hemagglutination both in the presence and absence of lactose or thiodigalactoside.
  • HL-60 cells and placenta tissue produce the preferred 14 kD ⁇ -gal binding lectin of the invention; this lectin is representative of the inventive class of 14- ⁇ -gal soluble lectins, one embodiment of which has at least one glycosylation site.
  • the phrase "14- ⁇ -gal mammalian lectin containing at least one glycosylation site" refers to a class of peptides having the characteristics of the group of lectins exemplified by the HL-60 lectin of Figure 1 which contain at least one tripeptide sequence. Asn-X-Thr or Asn-X-Ser. which provides a glycosylation site.
  • a peptide must exhibit the following biological properties:
  • a molecular weight of the nonglycosylated protein is approximately 14 kD.
  • the molecular weight ranges from about 12- 18 kD when it is measured by various techniques.
  • the lectin or fragment is capable of binding ⁇ -D-galactoside containing moieties (e.g. , lactose).
  • the inventive lectin causes hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays, in which the stimulation of agglutination is inhibited by moieties containing the ⁇ - galactoside linkage, such as lactose and thiogalactoside.
  • Hemagglutination can occur without a reducing agent, which is capable of maintaining thiol groups in the reduced form, but hemagglutination occurs without metal ions, in particular calcium ions.
  • the inventive lectins and fragments have at least 40% homology with the HL-60 lectin of Figure 1 , preferably at least 75% homology, more preferably over 90% homology and most preferably over 95%> homology.
  • the preferred location of the glycosylation site is at residues 96—99, as is the case for the lectin of Figure 1.
  • the glycosylation site can be within, at most, a four-amino acid spacing upstream or three-amino acid spacing downstream, i.e., between residues 92 and 101 inclusive.
  • Other preferred locations include those which contain Asn, X (any amino acid), and Ser/Thr residues in any of the animal lectins at nonconserved regions.
  • the most preferred embodiment of the 14- ⁇ -gal lectins containing glycosylation sites is that of the HL-60 lectin of Figure 1, particularly the lectin from HL-60 cell or placental tissue sources or a lectin from the naturally occurring mutants and allelic variants thereof.
  • glycosylation of these inventive lectins can be manipulated to provide different properties for therapeutic and diagnostic uses.
  • proteins exist in a variety of essentially equivalent forms including the acidic and basic salts thereof, forms which are derivatized at side-chain functional groups, forms associated with lipids and membranes, and other modifications made through post-translational processing of the cell expressing the DNA encoding the desired lectin. All of the proteins defined above are inclusive of these various forms.
  • the lectins of the invention can be isolated from native sources, synthesized, or produced by recombinant methods.
  • native sources such as HL-60 cells or placental cells
  • This publication also describes the retrieval of cDNA encoding HL-60 lectin.
  • the structure of the full length cDNA clone is shown herein in Figure 1.
  • the lectins and fragments of the invention can be prepared, if desired, by standard solid phase or other peptide synthesis methods. This mode of preparation is generally considered most suited for smaller peptide fragments. Although this method is clearly within the skill of the art with respect to the full-length lectin sequences, such as that shown in Figure 1, part or all of the molecule can more conveniently be synthesized using recombinant techniques.
  • the DNA which encodes the inventive lectin or fragment is mobilized by ligating the appropriate sequence to control sequences regulating expression, transfecting the resulting expression systems into appropriate hosts, and culturing the transformed or transfected hosts under conditions favorable for the expression of the DNA.
  • Genomic DNA encoding the HL-60 and placental lectin and its naturally occurring mutants and allelic variants can be recovered from the HL-60 or placental genome using the cDNA of Figure 1 as a probe.
  • the lectin-encoding sequence can be ligated into the expression system preceded by an ATG to obtain the lectin as a mature protein.
  • signal sequences known to be operable in the intended host such as the penicillinase or alkaline phosphatase system in bacteria, the alpha-factor system in yeast, or various hormone signal sequences in mammalian cells can be used to effect secretion by constructing the expression system with the DNA encoding signal in reading phase with the lectin DNA.
  • the lectin could also be produced as a fusion protein by ligating the coding sequence into reading frame with an additional coding sequence if desired.
  • E. coli are preferred, although other bacterial strains, such as Bacillus and Pseudomonas. could be used.
  • Suitable control systems include, but are not limited to, promoters associated with bacterial proteins such as ⁇ - lactamase and lactose (lac) promoter systems (Chang et al.. Nature ( 1977) _ 98: 1056; the tryptophan (trp) promoter system (Goeddel et al.. Nucleic Acids Res. (1980) 8:4057); and the lambda-derived P promoter and N-gene ribosome binding site system (Shimatake et al., Nature (1981) 292: 128).
  • lac lactamase and lactose
  • trp tryptophan
  • yeast systems includes, but is not limited to. the promoter for 3 -phosphogly cerate kinase (Hitzeman et al.. J. Biol. Chem. (1980) 255:2073), the enolase gene promoter (Holland. M.J.. et al.. J. Biol. Chem. ( 1981 ) 256: 1385), and the leu2 gene obtained from YEp 13 (Broach, J.. et al.. Gene (1978) 8:121).
  • the promoter for 3 -phosphogly cerate kinase Hitzeman et al.. J. Biol. Chem. (1980) 255:2073
  • the enolase gene promoter Holland. M.J.. et al.. J. Biol. Chem. ( 1981 ) 256: 1385
  • leu2 gene obtained from YEp 13 Broach, J.. et al.. Gene (1978) 8:121).
  • promoters operable in such cells include, but are not limited to, viral promoters such as the SV40 promoter (Fiers et al.. Nature (1978) 273:113) and promoters derived from adenovirus, bovine papilloma virus, Rous sarcoma virus, and so forth. Also usable are regulatable promoters such as the metallothionein I or metallothionein II promoters. Control sequences for retroregulation are also available such as that associated with the crystal protein gene of Bacillus thuringiensis.
  • the appropriate coding sequences are ligated to the control sequences in operable configuration and in suitable vectors for transfection into the intended host.
  • the vectors include, but are not limited to, plasmids, virus particles and phages depending on the intended host and the mode of transformation.
  • Transformation includes all forms of causing uptake of foreign DNA by a host cell including viral infection, transduction, conjugation or, probably most common, induction of uptake in vitro by transfection using transfecting agents such as calcium chloride or DEAE/dextran, depending on the host.
  • the transformed cells are then screened for those which contain the desired DNA and the successful transformants are cultured under conditions which affect the expression of the coding sequences.
  • the lectin produced is then purified from the medium (if the construction results in secretion) or from the lysed cells (if the construction results in an intracellular protein).
  • the lectin can be purified by standard methods, including extraction in lactose solution followed by chromatographic procedures. Convenient chromatographic procedures include chromatography on lactose sepharose gels, a sephadex S-200 HR column, or a lactose-HEMA column.
  • the presence of the protein in the active fractions can be easily detected by the ability of the fraction, after removal of the lactose, to cause hemagglutination of trypsinized rabbit erythrocytes, wherein the hemagglutination is inhibited by millimolar concentrations of lactose or thiodigalactoside.
  • the lectins of the invention can be used in conventional ways to raise antisera reactive with, and specific for, these lectins.
  • An antibody "specific for" the referenced lectin means an antibody which is immunoreactive with this lectin or. in some cases, with other lectins of the invention, but not immunoreactive with non-galactose binding lectins. Because of the extensive homology of the Figure 1 HL-60 lectin with other lectins of the inventive class, polyclonal antibodies raised against this lectin are likely to cross-react with other inventive lectins. However, by producing monoclonal antibodies with respect to this lectin, antibodies specific to one particular embodiment or to a selected group of inventive lectins can be generated. In addition, antibodies specific for various glycosylated forms can also be prepared.
  • Antibodies can be prepared using known techniques with specificities for any particular member of the inventive 14- ⁇ -gal lectin class, including those with at least one glycosylation site and in nonglycosylated and especially glycosylated forms.
  • the antibodies within the scope of the invention are those which are reactive with one or more members of the lectins of the invention, but the antibodies are not cross-reactive with the lectins presently known in the art. Also included in the scope of the invention are antisera raised by any of the lectins of the invention, since these antisera are unique to these lectins even if they contain antibodies which are cross-reactive in some measure with known lectins.
  • the lectins and fragments of the invention and their compositions are useful in a range of therapeutic and diagnostic applications. In general, these peptides and proteins are particularly useful as immunosuppressants.
  • the inventive lectins and fragments can be used in the treatment of autoimmune diseases such as myasthenia gravis. Other autoimmune diseases which are subject to treatment by these lectins include rheumatoid arthritis, systemic lupus erythematosus, juvenile diabetes, and multiple sclerosis. The inventive lectins can also be useful in controlling allergic reactions.
  • the inventive lectins and fragments can be administered in conjunction with various surgical transplantations including skin allografts, bone marrow transplants, and organ transplants such as kidney, heart, liver or lung transplants.
  • the lectins and fragments of the present invention can be administered along with amounts of known general immunosuppressants that enhance their effects.
  • suitable general immunosuppressants include, for example, cyclophosphamide, prednisone, cyclosporin, rapamycin, other macrolide derivatives such as FK506. azathioprine. mycophenolic acid, anti-Tac, lymphocyte immune globulin, and OKT3 antibodies.
  • the inventive lectins and fragments thereof can be administered simultaneously or sequentially with general immunosuppressants.
  • inventive lectins are useful in the treatment of neoplastic diseases characterized by a proliferation of lymphocytes, including, but not limited to leukemias.
  • T lymphocytic leukemia cells for example, have demonstrated susceptibility to lectin- mediated apoptosis particularly cells that express common leukocyte antigen (CD45).
  • CD45 common leukocyte antigen
  • Suitable targets for lectins are those cells of mammalian subjects with galactose-terminating ligands. These lectins are coupled to a drug, for example, cytotoxic or therapeutic agents, or to a label, by methods in the art.
  • a drug for example, cytotoxic or therapeutic agents, or to a label, by methods in the art.
  • antibodies specific for the inventive lectins are useful in targeting drugs or labels to tumors, since the level of certain lectins increases on the cell surface in metastatic cancer.
  • Anti-lectin antibodies are coupled to the drug, for example, a cytotoxic or therapeutic agent, or label.
  • the label coupled to the lectin or anti-lectin can be administered to a living mammalian subjects (in vivo use) or used in in vitro tests, for example, as part of a test kit.
  • the inventive lectins behave as immunomodulating agents and regulate the immune system by binding activated lymphocytes to other activated lymphocytes and to endothelial cells, for example on the inside of blood vessels.
  • Surface glycoproteins on resting lymphocytes contain terminal sialic acid residues, but activated lymphocyte glycoproteins are desialylated to expose galactose.
  • the inventive lectin is specific for activated T- cells and causes them to agglutinate or to adhere to endothelial cells. It is believed that these interactions may inhibit or modify T-cell migration, e.g. extravasation from the circulation, during inflammation. i. Induction of Apoptosis
  • the inventive lectin which is expressed by stromal cells in human thymus and lymph nodes (Baum, L.G., Pang, M., Perillo, N.L., Wu, T. & Seilhamer, J.J. J. Exp. Med. 181:877-887 (1995); Seilhamer, J.J.. Pang, M., Perillo, N.L. & Baum. L.G. J. Cell Biochem. 17A:373 (1993)), is present at sites where cell death by apoptosis occurs during normal T cell development and maturation. Regulation of apoptosis involves events that are only partially understood.
  • the inventive lectin may affect the immune response by another route.
  • Antibodies specific for the inventive lectin have been observed reacting with human thymic tissue. particularly thymic cortical epithelial cells whose interaction with immature cortical thymocytes is crucial in deleting auto-reactive T-cells.
  • thymus typically atrophies early in life and is not known to play an active role in adult autoimmune pathology
  • administration of the inventive lectin may possibly increase thymic deletion of autoreactive T-cells.
  • Administration of antibodies which specifically bind the inventive lectin may be useful in the treatment of such tumors by blocking the immunosuppressive effect of lectin on the tumor infiltrating T lymphocytes.
  • the treatment of lectin-producing tumors may also be accomplished by the adminstration of a lectin antagonist, typically a small peptide that binds specifically to lectin will also prevent lectin-induced apoptosis of tumor-infiltrating T cells.
  • a lectin antagonist typically a small peptide that binds specifically to lectin will also prevent lectin-induced apoptosis of tumor-infiltrating T cells.
  • T cells are important in lectin-induced apoptosis.
  • administration of an effective amount of a glycosylation inhibitor such as swainsome may also be effective in the treatment of lectin-producing tumors by preventing glycosylation of tumor-infiltrating T cells.
  • the nonglycosylated T cells are not affected by the lectin and. therefore, are able to infiltrate the tumor.
  • Glycosylation inhibitors, such as swainsome are effective in preventing lectin-induced apoptosisy is bound by v.
  • Inhibitory Saccharides Certain glycans, particularly N-glycans bind lectin and may be particularly effective in preventing lectin-induced apoptosis of tumor-infiltrating T cells.
  • the inhibitory saccharides are administered by flooding the tumor, thereby exposing the lectin produced by the tumor to the saccharide and thereby preventing the lectin from interacting with the tumor-infiltrating T cells to cause apoptosis.
  • the lectins and fragments are formulated in a manner suitable for the desired mode of administration using formulation technology known in the art as described, for example, in Remington's Pharmaceutical Sciences. 17th edition. Mack Publishing Co., Philadelphia. PA.
  • Typical formulations for injection include admixture with physiological buffer for injection such as Hank's solution or
  • Ringer's solution encapsulation in liposomes or other emulsifying agents suited for drug delivery, and the like.
  • a particularly preferred method of formulation provides for long term storage of the soluble lectin of this invention in the lyophilized, or freeze-dried, form.
  • Lyophilization is preferably conducted in the presence of a concentration of a carbohydrate which is effective to stabilize the lectin during the lyophilization process and at a relatively low pH of about 5. This pH appears to minimize oxidation.
  • Suitable protective carbohydrates include, but are not limited to, monosaccharides such as galactose; disaccharides such as lactose, maltose and sucrose; and oligosaccharides containing galactose moieties.
  • the preferred carbohydrates are lactose and maltose.
  • the most preferred protective carbohydrate is lactose. Because the lyophilized product is used in a pharmaceutical composition, the protective carbohydrate must be physiologically and pharmaceutically acceptable at the concentrations used.
  • the effective concentration of the protective carbohydrate can be 1 ⁇ 10% wt. /volume but is preferably around 5-15%, and even more preferably around 10%.
  • the maintenance of the pH at about 4 to 8, preferably at about 4.5 to 6. and more preferably at about 5 discourages oxidation of cysteine residues. It is further preferable to maintain this pH in a buffer of relatively low ionic strength, since the freezing point of the mixture is then not lowered significantly.
  • the buffer is bicarbonate, gluconate, lactatc. acetate or phosphate.
  • the buffer is citrate. It is preferred that the buffer concentration be about 5-20 mM. more preferably 7-12 mM, and most preferably about 10 mM. Other conditions of lyophilization can also be used; however, it has been found that the presence of about 10% lactose in about 10 mM citrate and a pH of 5 are particularly favorable conditions.
  • the dosage level and manner of administration of the lectins and fragments of the invention depends on the indication and the subject, as well as the severity of the condition to be treated. When the full lectin is administered, a higher dose (mg/day) is required than when active fragments of the lectin are administered. Some indications for use (such as transplantation rejection, particularly full-blown rejections) require higher doses than to others (such as rheumatoid arthritis, particularly between flare-ups of the disease).
  • the subject who receives the inventive lectin can be a mammal, bird or other vertebrate, because the lectins of mammals, birds, eels, and fish have been found to be related.
  • the term subjects refers to mammalian subjects, including humans, farm animals, sport animals and pets. Farm animals include, but are not limited to, cows, hogs and sheep. Sport animals include, but are not limited to. dogs and horses.
  • the category pets includes, but is not limited to, cats and dogs. Smaller animals generally require somewhat higher doses per kilogram.
  • inventive dose levels range from about 0.004 mg/kg/day to about 2 mg/kg/day.
  • inventive lectins are used in conjunction with general immunosuppressants, however, lower dosages are generally preferred.
  • inventive lectins or fragments are administered in a manner suitable for peptides or proteins — i.e., by injection or by other parenteral routes including transmembrane or transmucosal transitions. Formulations suitable for these modes of administration are well understood in the art. Oral administration is always desirable, provided the formulation permits the substantially intact lectin or fragment thereof to survive the digestive tract and enter the bloodstream.
  • E. coli containing an expression plasmid in which the DNA to be expressed is that shown in Figure 1
  • LB Luria broth
  • the cells were then frozen and the lectin was extracted by purification procedures.
  • the frozen cell samples were thawed in ice overnight or under cool running water to expedite the thawing.
  • the cells were collected in a beaker and slowly mixed with a 15 mM ⁇ -mercaptoethanol (B-ME) buffer to form a thin paste having a density of approximately 0.1 to 0.3 g/ml.
  • the buffer was a solution comprised of O.02M Tris, 0.15M NaCl, 0.002M EDTA, and 15mM Mercaptoethanol having of pH of 7.5.
  • the cells and buffer were maintained in a cold environment.
  • the cold environment is a room that is maintained between 2 and 6° C.
  • the cells and buffer were mixed for a time period as long as two hours until a homogeneous, lump-free, cell suspension results.
  • Magnetic mixers, overhead mixers or other well known mixers or other mechanical disruption devices could be used.
  • the overhead mixer has been most effective for mixing large amounts of cells.
  • the cell suspension was passed twice through a high pressure Microfluidics homogenizer, operated at 15,000 psi.
  • the homogenizer was packed in ice to prevent heating of the cell suspension.
  • Tris buffered saline (TBS) was used to recover the disrupted cell product obtained from the homogenizer.
  • the disrupted cells were next placed in an RC5B centrifuge (DuPont de Nemours, Wilmington. DE) at the maximum speed (approximately 8000 rpm) for thirty minutes to separate cell debris.
  • the centrifuged cell product was next decanted to separate the protein supernate from the cell pellets.
  • the supernate contains the desired lectin.
  • the cell pellets can be quick frozen on dry ice for later possible application.
  • the supernate was mixed with an aqueous solution containing 10% by volume. pH 8.0, polyethylenimide (PEI). The supernate/PEI mixture was stirred slowly in a cold environment for approximately one half hour. A milky white precipitate formed which contains the desired nucleic acids. The mixture containing the precipitate was next placed in the centrifuge at the maximum speed (approximately 8000 rpm) for 20 to 30 minutes to remove the precipitated nucleic acids. A clear yellow/tan supernate was obtained from this second centrifugation process. The yellow/tan supernate can be stored at 4°C overnight before processing it through chromatography columns the next day.
  • PKI polyethylenimide
  • PEI can be added before the first centrifugation step, instead of before the second centrifugation step, which can then be skipped.
  • the addition of PEI before the second centrifugation step is preferred because it preserves the cell pellets without the added protein of the PEI precipitate. Furthermore, testing revealed that no loss of product resulted by adding the PEI before the second centrifugation step. However, since the second centrifugation step adds at least one additional hour to the total process time, an alternative method of adding PEI before the first centrifugation step can be used to make this claimed invention in less time.
  • the next step was chromatography on lactose Sepharose gels.
  • the lactose Sepharose column (Pharmacia, Uppsala, Sweden) was equilibrated with TBS and MCE buffer.
  • the yellow/tan supernate was loaded onto the column at 12 to 20 cm/hr.
  • the column was washed with equilibrium buffer at 20 to 25 cm hr until UV absorbance returned to baseline.
  • the column flow was reversed, and the buffer wash was continued for a time period equal to the time it would take to fill one-half of the column at the desired flow rate.
  • the product was then eluted with 0.1M lactose in gradient form.
  • the gradient method of elution is preferred for smaller quantities; however, the batch method is preferred for larger quantities.
  • An alternative chromatographic procedure involves ion-exchange chromatography on a Sephadex S-200 column (Pharmacia).
  • the column is depyrogenated using sodium hydroxide washes of decreasing concentration.
  • the S-200 column is next equilibrated with 10 mM citrate, having a pH of 5.0.
  • the yellow/tan supernate is loaded onto the column at a rate of approximately 15 cm/hr.
  • the supernate can be loaded at a rate up to 6 % by volume of the total solvent exchange.
  • the product concentration at loading should be as high as possible to eliminate or minimize the need to further concentrate the eluted product.
  • the eluted product is diluted in a 1 : 1 ratio with sterile-filtered 10% Lactose in 10 mM Citrate having a pH of 5.0.
  • a further alternative chromatographic procedure includes the use of a Lactose- HEMA column.
  • the eluted product obtained from the above chromatographic procedure was stored in small vials, with about 1 to 5 ml of the product in the appropriately sized vial.
  • the vials were sterilized prior to filling by heating the vials to about 150°C for a minimum of 4 hours. Any leak tight caps, such as grey split stoppers, can be used to contain the product within the vial.
  • the product was next lyophilized using a Virtis lyophilization chamber or unit.
  • the vials containing the product were placed in the unit's chamber and frozen to -30°C. This temperature was maintained for at least 3 hours.
  • a vacuum was applied to the chamber and the pressure was reduced to less than about 100 torr and preferably about 15 torr.
  • the Virtis unit was maintained at -30°C and 15 torr for at least two hours.
  • the unit and vials were brought to 0°C and maintained at this temperature for at least two hours.
  • the temperature was further increased to 30°C in 5°C increments over a six hour period. Once the 30°C temperature was reached, the unit was maintained at 30°C for at least two more hours.
  • the vials were then sealed under vacuum with stoppers and aluminum seals, over which vial caps were crimped.
  • the recombinantly produced and purified lectin described above was tested to assure that it has the same electrophoretic and chromatographic mobility, the same N- terminal amino acid sequence, and the same immunoreactivity on Western blots as that of the 14 kD inventive lectin derived from either human placenta or HL-60 cells.
  • a test was devised to discover whether these lectins bind lymphocytes and/or T-cells to endothelial cells. Thin sections of tissue containing inflamed rat brain vascular endothelium were prepared. Rat lymph node lymphocytes and human T-cells of the Jurkat line ( 10 ⁇ /ml in Dulbecco's modified Eagle medium (MEM) with 5% fetal bovine serum (FBS)) were treated with 250 ⁇ g/ml of the lectin of Example 1. with the lectin plus 1 mM lactose, or with no additions and subsequently were placed on ice for 30 min. The lectin severely agglutinated the T-cells and moderately clumped the rat lymphocytes. These effects were not observed when lactose was added or when there were no additions.
  • MEM Dulbecco's modified Eagle medium
  • FBS fetal bovine serum
  • lectin enhances binding of rat lymphocytes to vascular endothelium by reacting with both the endothelium and with the lymphocytes and serving as a molecular bridge.
  • the lectin did not similarly bind T-cells to endothelium, possibly because the T-cells were so thoroughly agglutinated that no free cells were available to bind the endothelium.
  • lymphoid organs lymph nodes and Peyer's patch
  • Lectin had no noticeable effect on rat lymphocytes: however, because control level binding was very low. this result cannot be relied on.
  • anti-lectin antiserum was prepared by injecting the inventive recombinant lectin into rabbits. Polycional antiserum specific for the inventive lectin was obtained from the immunized rabbits. Slides were made of sections of human thymic cortex and of cultured thymic epithelial cells. These sections of human thymic tissue and cultured thymic epithelial cells were incubated with the rabbit anti-lectin antisera.
  • the cross-reactivity was detected at a dilution of 1 : 1000 by labeling the antibody-coated sections with goat anti-rabbit horseradish peroxidase and adding substrate.
  • the thymic sections were examined by microscopy and had highly stained thymic cortical epithelial cells.
  • the cultured thymic epithelial cells were also highly stained.
  • the epithelial nature of the stained thymic cells was confirmed by counterstaining with cytokeratin antibodies which are specific for epithelial cells. See Figure 2 for the comparison of anti-lectin staining and anti-cytokeratin staining.
  • a protein which is immunologically cross-reactive with the inventive recombinant lectin has been localized to epithelial cells in human thymic tissue.
  • protein extracts of cultured thymic epithelial cells stained positively with the rabbit-polyclonal antiserum on Western blots in an immunoreactive band which comigrated with the inventive lectin.
  • thymic cortical epithelial cells have a protein with a molecular weight, antigen reactivity and DNA sequence similar to those properties of the inventive lectin. Because interaction between thymic epithelial cells and immature cortical thymocytes is crucial for proper selection of immunocompetent T-cells. the inventive lectin appears to affect thymocyte maturation. In addition, in comparison to mature T- cells.
  • immature cortical thymocytes show much higher levels of the galactose ligand which is recognized by the inventive lectin. This further supports interaction of the inventive lectin with immature thymic cells, rather than an effect on mature T-cells.
  • galactose-terminating ligands are present on the cell surfaces of migrating leukocytes and could be responsible for leukocyte recognition by lcctin- containing homing receptors. Because the inventive lectins are specific for galactose ligands. the inventive lectins should affect the extravasation caused by leukocyte-receptor interaction. This can also be conveniently tested.
  • T-cell lines MOLT4 and ARR a T-cell line with sialic-acid-terminating glycoproteins
  • neuraminidase which cleaves terminal sialic acids from the glycoproteins on ARR cells and leaves terminal galactose
  • galactosidase endolactosaminidase or no enzyme.
  • the cells were incubated with and without lectin.
  • T-cells All the treatment and control groups of T-cells were layered over thymic epithelial cells, incubated and washed as described in Singer et al. Lastly, the amount of bound T-cells was quantitated by decompositions per minute (DPM). Only lectin-treated T-cells with terminal galactose residues appreciably bound to thymic epithelial cells, as shown in Figure 4.
  • DPM decompositions per minute
  • Biological activity of the inventive 14 kD lectins 1 ) isolated from HL-60 cells, 2) isolated from placenta tissue or 3) prepared recombinantly from E. coli cells transfected with lectin cDNA operably linked to a secretion signal was ascertained by agglutination of trypsinized rabbit erythrocytes.
  • the top row shows a Concanavalin A control with an agglutination end-point at 1.5 ⁇ g/ml.
  • the lower six rows show the three purified inventive 14 kD lectins incubated with varying concentrations of completing sugars, ⁇ -lactose and thiodigalactoside, which are known to be potent inhibitors of the 14 kD placental lectin.
  • Thiodigalactoside inhibited agglutination of the erythrocytes at concentrations greater than 0.31 mM and ⁇ -lactose inhibited agglutination at concentrations greater than 1.25 mM.
  • Example 5 Effect of 14 kD ⁇ -gal Lectin in a Myasthenia Gravis Model
  • Experimental autoimmune myasthenia gravis is an antibody-mediated autoimmune disease responding to acetylcholine receptors (AChR).
  • This condition in mice is a recognized model for studying the effects of the autoimmune response on neuromuscular transmission (Levi, G. et al.. Eur. J. Immunol. ( 1983) ]_3:500-507; Lefvert, A.K. et al.. Scand. J. Immunol. (1978) 8:525: Lefvert, A.K. et al.. J. Neuro. Immunol. ( 1985) 9:41 ; Lefvert, A.K.
  • T helper cells which produce acetylcholine receptor antibodies.
  • the disease is induced in mice by injection of acetylcholine receptor.
  • the acetylcholine receptor is obtained from the electric organ of the ray Torpedo marmorata and purified by affinity chromatography on Naja naja siamensis neurotoxin crosslinked to Sephadex.
  • mice Young adult female BALB/c and C57B/6 mice (2-4 months of age) were used because they differ in EAMG susceptibility.
  • the mice were injected subcutaneously with 10 ⁇ g of purified acetylcholine receptor, in Freund's complete adjuvant without and with the 14 kD- ⁇ -gal lectin. Blood was obtained after 3 days and after 1 , 2, 3 and 4 weeks.
  • the mice were observed daily for signs of neuromuscular dysfunction and after 10 days subjected to forced exercise using repetitive grasping, swimming and inverted hang. These exercises were repeated after warming under a heat lamp at 35°C for 5 min.
  • Table 2 The results of these observations are presented in Table 2 and show that in both strains of mice tested at higher lectin dose levels, the recombinant lectin markedly slowed neuromuscular deterioration.
  • a cholinergic receptor (AChR) extract was prepared as described by Lefvert. A.K. et al., Scand. J. Immunol, supra for determination of total AChR content and Ig-complexed AChR content, as described therein.
  • mice AChR+lectin (0.1 ⁇ g) AChR+lectin (l ⁇ g) AChR+lectin (5 ⁇ g) AChR+lectin (15 ⁇ g) AChR+lectin (25 ⁇ g) AChR only
  • mice Three BALB/c female mice (7-8 weeks old) were injected intraperitoneally with 5 ⁇ g of AChR antibody, tetanus toxoid or pneumococcal polysaccharide. respectively, in complete Freund's adjuvant. Two weeks later, the mice were injected intravenously with the same amount of antigen in 0.15 M sodium phosphate buffer, pH 7.4. Tetanus toxoid was obtained from the Swedish National Bacteriological Laboratory and consisted of formalin-treated tetanus toxin (normally used for vaccination).
  • a mixture of capsular polysaccharide extracts from 23 different serotypes of Streptococcus pneumomae was obtained from Merck Sharp & Dohme, Inc. (West Point, PA). Three other mice of the same strain were similarly immunized with these antigens in combination with 15 ⁇ g of the recombinant lectin; controls received only the antigens. g The animals were sacrificed 4 days after the booster injection and spleen cells (10
  • mice peritoneal macrophages 5 x 10 cells/well. From the third day in culture HAT (hypoxanthine-aminopterin-thymidine) medium was added. After 10-
  • microtiter wells were coated overnight with 100 ⁇ l of a solution containing 5 ⁇ g/ml of purified receptor as prepared in Example 8, Part A, and incubated with serum (diluted 1/25) for 3 hours at 37°C. After washing, the plates were incubated for 3 hours at 37°C with alkaline phosphatase-conjugated goat anti-mouse immunoglobulins. The plates were then washed extensively and incubated for 1 hour at 37°C with p-phenylphosphate ethanolamine buffer.
  • the reaction was stopped by addition of 25 ⁇ l of 3 M NaOH, and the binding of the labeled antibody was measured in an ELISA microreader at 405 nm.
  • a normal mouse serum pool from more than 50 mice served as negative control.
  • the cut-off limit was the mean +4SD of cumulated values obtained with this normal serum pool.
  • the results were compared to results obtained by radioimmunoassay and expressed in moles of toxin receptor precipitated by 1 liter of serum, after subtraction of the mean +4SD of cumulated results from a normal population (more than 50 mice).
  • antibodies against mouse AChR antibodies were determined using as antigen a complex between a partially purified normal mouse skeletal muscle receptor and P ⁇ 5 I- alpha-bungarotoxin. The results were expressed in moles of toxin receptor precipitated by 1 liter of serum, after subtraction of the mean +4SD of cumulated results from a normal population (more than 50 mice).
  • microtiter wells were coated overnight with 100 ⁇ l of a solution containing 5 ⁇ g/ml of the antigen and incubated with serum (diluted 1/200) for 3 hours at 37°C. After washing, the plates were incubated for 3 hours at 37°C with alkaline phosphatase-conjugated goat anti-mouse immunoglobulins. The plates were then washed extensively and incubated for 1 hour at 37°C with p-phenylphosphate ethanolamine buffer. The reaction was stopped by addition of 25 ⁇ l of 3 M NaOH, and the binding of the labeled antibody was measured in an ELISA microreader at 405 nm.
  • the cut-off limit was the mean +4SD of cumulated values obtained with this normal serum pool. The values were expressed in milliabsorbance units after subtraction of the mean +4SD of the normal serum pool.
  • mice Groups of BALB/c mice were immunized with tetanus toxoid, pneumococcal polysaccharide, ray Torpedo receptor and mouse receptor without and with various doses of recombinant lectin. Blood was obtained after 3 days and again after 1 , 2, 3 and 4 weeks and antibody levels were determined as described above.
  • EAE Experimental autoimmune encephalomyelitis
  • GPBP guinea pig myelin basic protein
  • CFA Complete Freund's Adjuvant
  • T-cells specific for GPBP in immunized rats recognize amino acid residues 72-89 of GPBP and have the ability to transfer both clinical signs of EAE and delayed-type hypersensitivity reaction to GPBP to other animals.
  • EAE was induced by injection of GPBP/CFA as described above.
  • intravenous administration of lectin was started at day 0 relative to 50 ⁇ g GPBP/CFA injection, with additional lectin treatment at days 3 and 6.
  • the severity of the disease was determined clinically and histologically: "Clinical" ratings are as follows:
  • lectin was first administered three days before immunization with 50 ⁇ g GPBP/CFA and was followed by daily injections until day 7 after immunization. As shown in Table 6, with this protocol, the development of the disease was prevented completely.
  • Figure 10 shows the severity of the disease with lectin dosages ranging from 10- 1500 ⁇ g intraperitoneally.
  • Figure 1 1 shows a summary representation of these results computed on day 12. As determined from Figures 10 and 1 1 , a daily dosage of 500 ⁇ g appears optimal for ameliorating the symptoms of experimental autoimmune encephalitis.
  • lymph nodes draining the site of injection were collected and tested for a proliferative response to GPBP.
  • purified protein derivative PPD
  • Concanavalin A Concanavalin A
  • lymph node cells of the lectin-treated rats had low or absent responses to both GPBP and PPD relative to control rats, especially on days 14 and 21 during which EAE onset occurs.
  • Responses to ConA in treated rats were normal or augmented, however, indicating lack of global immunosuppression.
  • lymph node cells were also unresponsive to the inventive lectin (data not shown), indicating that the lectin was not mitogenic.
  • the sera of treated rats did not contain antibodies specific for the lectin as measured by ELISA.
  • T-cell lines were selected from the draining lymph nodes. Although GPBP-specific T-cell lines could be raised from the GPBP/CFA immunized control group, no responses were observed to GPBP and no lines could be established from the lectin-treated rats. In separate experiments, lectin added to established T-cell lines had no inhibitory effect, however. Taken together, the data show that the inventive recombinant lectin is potent in preventing primary sensitization to both GPBP and PPD, but did not affect T-cell responses generally, as shown by full T-cell responses to ConA.
  • Example 9 Effect of the Inventive 14 kD Lectin on EAE Relapse
  • mice An additional murine model of EAE was used to demonstrate the effect of the inventive lectin on this condition.
  • symptoms of EAE can be made to occur in cyclical fashion by boosting the animals with antigen following each cycle, and each cycle becomes more severe until death ultimately occurs.
  • This is a useful model in which to determine therapeutic efficacy, since it closely mimics both the chronic disease relapses and the acute demyelination associated with multiple sclerosis.
  • 20 female SJL/J mice were immunized with lyophilized spinal cord extract dissolved in PBS plus CFA on days 0, 7 and 21. Ten mice were injected with recombinant lectin, and ten mice were given buffer only.
  • mice received 50 ⁇ g lectin on days 13 and 15 intravenously in the tail vein, and an additional 100 ⁇ g i.v. daily from day 18 through day 24. Mice were followed until death or sacrifice at day 42.
  • the results in Figure 13 are mean clinical scores for control and lectin-treated mice.
  • Lectin-treated mice had improved clinical scores during the first cycle, and improved survival and clinical scores through the second cycle.
  • Example 10 Effect of Lectin Treatment on Transplant Acceptance and Rejection
  • the studies reported here relate to Brown Norway rat tissue transplanted into Lewis rats.
  • This model a highly histo-incompatible donor/recipient pair, provides a very stringent test with predictive value in human transplantation.
  • Known general immunosuppressive agents show immunosuppressive activity in these models.
  • Several forms of this model are used in the studies reported here.
  • a control group comprised twelve recipients treated daily i.v. only with buffer control.
  • the graft survival times were: 6d (x4), 7d (x7). and 8d, giving a mean survival of 6.82 + /-0.6d (SD).
  • the final day of survival is defined as the day on which the donor heart ceased to contract as assessed by lack of obvious palpitations and as confirmed by direct visualization at laparotomy.
  • mice Five recipients were treated with the recombinant lectin. All animals were pretreated with 1 mg/kg i.v. lectin on days -3. -2 and -1. The first two animals were then treated postoperatively with 1 mg/kg/d i.v. with lectin from day 1 until graft rejection. The second three animals were treated in the postoperative period from day 1 until graft rejection with 2 mg/kg/d i.v. of lectin. Graft survivals were 9 and lOd for the first group of rats, and 9, 10 and 1 Id for the second group. No dramatic increase in survival was seen by doubling the dose of lectin in group two in the post-operative period. Therefore, graft survival times of both groups were combined for statistical analysis.
  • Cyclosporin i.p. was started the day of the graft and continued daily. Recombinant lectin was started two days prior to transplant and continued daily.
  • the number of survivors on day 16 are shown in Table 8.
  • the group receiving cyclosporin alone was unusually long lived, since animals on such therapy typically die within two weeks.
  • the combination therapy had a higher survivor rate than cyclosporin or lectin administered alone or the sum of the two survival rates.
  • the differences between control and test groups decreased, which may be attributed to 1) the unusually longevity of the cyclosporin-treated rats and 2) the immunogenicity of human lectin in rats.
  • Table 1 1 A shows a 28% increase in the number of rat lymph node suppressor T- cells (reactive with monoclonal antibody 0X8, Serotec-Bioproducts, Indianapolis. IN) from lectin-treated animals.
  • Table 1 IB shows a 32% increase in the number of spleen suppressor T -cells as well as a 19% and 24% decrease in the numbers of helper T-cells (w3/25 antibody reactive, Serotec-Bioproducts) and total T-cells (w3/13 antibody reactive, Serotec- Bioproducts), respectively.
  • Human blood cells were pretreated with the inventive HL-60 lectin and then stained with fluoresceinated antibody having several different specificities. Control cells were not pretreated with lectin.
  • the results in Table 12 show that recombinant human lectin specifically reacts with human macrophages. No significant changes were observed for CD3+, CD4+, NK(L-A) or HLA-DR cell markers (Becton-Dickinson). However, the effect of lectin treatment on M 1 and M3 macrophages was significant. The percent of positive cells was reduced by 33% and 26%, respectively, suggesting an interaction between lectin and epitopes recognized by Ml and M3 antibodies.
  • Recombinant lectin within the instant invention induces apoptosis of activated human T cells by the criteria of morphologic changes and the induction of DNA fragmentation.
  • Membrane blebbing, margination of chromatin and cell shrinkage were visible within 90 minutes after lectin treatment, and apoptotic bodies appeared within 5 hours.
  • An increase in the number of cells with hypodiploid DNA content in samples was detected in samples treated with lectin relative to control samples (see Figures 15A and B).
  • PBMs human peripheral blood mononuclear cells
  • PHA phytohemagglutinin
  • PHA phytohemagglutinin
  • complete medium RPMI 1640, lOmM Hepes, 10% fetal bovine serum
  • Day 5 blasts were centrifuged over Ficoll-Paque® (Pharmacia) to enrich for viable cells, then cultured for 8 hours at 37°C in complete medium with 3mM dithiothreitol (DTT, Sigma Chemical Co.), with (Fig. 15B) or without (Fig. 15A) 16 ⁇ M of lectin.
  • Example 14 Only Activated T cells are Susceptible to Lectin-induced Apoptosis The apoptotic effect of the lectin depended upon the activation state of the T cells.
  • FIG. 16A and 16B both resting and activated T cells bound lectin. In contrast, only activated T cells underwent apoptosis when exposed to lectin.
  • Figure 16C demonstrates that 35% of activated T cells treated with lectin underwent apoptosis, while 7% of peripheral blood mononuclear cells (PBMs) underwent apoptosis in response to the lectin.
  • PBMs peripheral blood mononuclear cells
  • CEM cells were not susceptible to lectin, in contrast to reports that CEM cells are sensitive to both anti-Fas and corticosteroid-induced apoptosis.
  • Some cell lines may lack one or more components of the signaling pathway necessary for lectin-induced apoptosis, which may be different than the pathways used by other agents.
  • Confluent monolayers of HAECs plated on 15 mm coverslips in Ml 99 with 20% FBS were treated with 100 ⁇ g/ml of MM-LDL or buffer (PBS, 0.01% EDTA, 10 ⁇ M butylated hydroxytoluene) for 4 hours at 37°C.
  • MOLT-4 cells (3.3 X 10° per well) were added to HAEC monolayers or to control wells with and without MM-LDL for 4 hours at 37°C. After removal of unbound cells by washing, the coverslips were fixed in 4% paraformaldehyde and stained by in situ nick end-labeling as in Figures 15C and 15D. Cytospin preparations were made from control wells and similarly stained.
  • the number of adherent MOLT-4 cells and the percentage of labeled apoptotic cells were determined by light microscope examination. Twenty-four high power fields were counted for each sample and the percentage of apoptotic cells was calculated as the mean value ⁇ s.d. from a representative of two experiments.
  • PBMs Fig. 16C
  • day 5 PHA blasts Fig. 16D
  • biotinylated lectin 14 ⁇ M
  • cells were stained with phycoerythrin- conjugated streptavidin (Molecular Probes) and analyzed by flow cytometry on a Becton- Dickinson FACSCAN®
  • T cell surface glycoproteins contain polylactosamine sequences preferentially recognized by the inventive lectin.
  • an ELISA assay was used to detect the binding of lectin to the MOLT-4 T lymphoblastoid cell line in the presence and absence of antibodies directed against T cell surface glycoproteins.
  • Antibodies directed against leukosialin (CD43) and leukocyte common antigen (CD45) significantly inhibited lectin binding to the T lymphoblastoid cell line MOLT-4 (Fig. 17A).
  • CD43 and CD45 have been shown to be T cell counter-receptors for lectin expressed by thymic epithelial cells.
  • CD45 has a cytoplasmic phosphatase domain and has been proposed to participate in apoptosis in the thymus. (Ong, C.J., Chui, D., The, H.-S. & Marth. J.D. J. Immunol 152:3793-3805 (1994)).
  • lectin-mediated apoptosis the ability of the lectin to induce apoptosis of the human T cell line HPB- ALL and a variant of this cell line, HPB.45.0 which does not express CD45 was investigated (Koretzky, G.A., Picus, J.. Thomas M.L. & Weiss, A. Nature 346:66-68 (1990)).
  • Antibodies were obtained from the following sources: T305 (CD43) the gift of Dr. Robert Fox (Scripps Clinic and Research Foundation); LCA (CD45) Dako Corp.; MHM4 (CD1 la), and IOL44 (CD44) AMAC. Inc.; TI (CD5) Coulter: DX2 (CD95) PharMingen; Leu-28 (CD28) Becton-Dickinson.
  • the T cell lines HPB-ALL and HPB.45.0 were incubated in complete medium. 3mM DTT at 10 X 10 ⁇ cells/ml in the presence (unshaded) and absence (black) of 16 ⁇ M lectin. After 5.25 hours at 37°C. the cells were fixed in ethanol and the percent of apoptotic cells was determined by morphological analysis after staining with 7-AAD. Results are expressed as the mean ⁇ s.d. of triplicate samples from a representative of three experiments. HPB-ALL and HPB.45.0 cells were the gift of Dr. Arthur Weiss (Univ. of California. San Francisco).
  • CD45 The Effect of Inhibitors of Glycosylation on the Susceptibility of activated T cells to Lectin-induced Apoptosis CD45 exists in a number of isoforms, which are expressed in a regulated fashion during thymocyte development and T cell activation (Pulido, R. & Sanchez-Madrid, F. Eur. J. Immunol. 20:2667-2671 (1990)).
  • the core of CD45 present on all isoforms, bears eleven N-glycans.
  • the higher molecular weight forms of CD45 present on medullary thymocytes and naive peripheral T cells, contain amino terminal domains which are heavily O-glycosylated.
  • Both N- and O-glycans on CD45 can contain the polylactosamine sequence preferentially recognized by the inventive lectin.
  • the carbohydrates expressed on CD45 are important in lectin-induced apoptosis and susceptibility to apoptosis increases with activation.
  • the relative contributions of N- and O-glycans to lectin-induced cell death was investigated by culturing activated T cell blasts with swainsonine or benzyl-u-GalNAc.
  • Swainsonine inhibits the processing of N-linked oligosaccharides by inhibiting mannosidase II.
  • Benzyl-u-GalNAc inhibits O-linked oligosaccharide chain elongation.
  • Cells cultured with the inhibitors were tested for the ability to bind to lectin, and for susceptibility to lectin-induced cell death.
  • swainsonine treatment decreased the binding of lectin to T cells.
  • Swainsonine also reduced lectin-induced cell death relative to untreated cells.
  • Swainsonine treatment did not affect the level of expression of CD45 or CD43, as determined by flow cytometric analysis.
  • Benzyl- ⁇ -GalNAc treatment also decreased lectin binding.
  • Benzyl- ⁇ -GalNAc potentiated the cytotoxic effect of the inventive lectin, resulting in an increase in lectin-inducible cell death.
  • O-glycans may modulate the effect of lectin.
  • the inhibition of O-glycan elongation by benzyl- ⁇ -GalNAc may have unmasked N-linked polylactosamine structures involved in the apoptotic signal. (Perillo, N.J., Pace, K.E., Seilhamer, J.J. & Baum, L.G. Nature 378:736-739 (1995)).
  • the masking of oligosaccharide ligands on the surface of natural killer cells was recently proposed to protect NK cells from self-cytolysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à des procédés de traitement de maladies néoplasiques caractérisées par la prolifération de lymphocytes. Lesdits procédés consistent à administrer des compositions pharmaceutiques contenant une lectine soluble possédant un poids moléculaire d'environ 14 kilodaltons. L'invention se rapporte en outre à des procédés de traitement de tumeurs productrices de lectine qui consistent à administrer une quantité efficace d'un anticorps qui se lie de manière spécifique à la lectine, aux antagonistes de la lectine, à des saccharides inhibiteurs ou à des inhibiteurs de glycosylation dans le but de prévenir l'apoptose induite par les lectines des lymphocytes T infiltrés dans la tumeur.
PCT/US1997/015016 1996-08-26 1997-08-26 Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60 WO1998008535A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40913/97A AU4091397A (en) 1996-08-26 1997-08-26 Method of causing selective immunosuppression using hl-60-related lectins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70480296A 1996-08-26 1996-08-26
US08/704,802 1996-08-26

Publications (2)

Publication Number Publication Date
WO1998008535A2 true WO1998008535A2 (fr) 1998-03-05
WO1998008535A3 WO1998008535A3 (fr) 1998-05-28

Family

ID=24830917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015016 WO1998008535A2 (fr) 1996-08-26 1997-08-26 Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60

Country Status (2)

Country Link
AU (1) AU4091397A (fr)
WO (1) WO1998008535A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006724A1 (fr) * 1998-07-31 2000-02-10 Kirin Beer Kabushiki Kaisha Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active
US20060110779A1 (en) * 2004-11-22 2006-05-25 National Cheng Kung University Method for detecting a lectin-like substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096557T3 (es) * 1988-04-14 1997-03-16 Incyte Pharma Inc Lectinas 14-beta-gal de mamiferos.
WO1992019239A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
AU5608594A (en) * 1992-11-16 1994-06-08 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006724A1 (fr) * 1998-07-31 2000-02-10 Kirin Beer Kabushiki Kaisha Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active
US6890531B1 (en) 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
US20060110779A1 (en) * 2004-11-22 2006-05-25 National Cheng Kung University Method for detecting a lectin-like substance

Also Published As

Publication number Publication date
AU4091397A (en) 1998-03-19
WO1998008535A3 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
US5693760A (en) Method of causing selective immunosuppression using HL-60 related lectins
KR100386046B1 (ko) 폴리펩티드 및 이를 암호화하는 핵산
Nishimura et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver.
JP2008073041A (ja) 組換え型ヒトα−フェトプロテインおよびその利用
JPH08510257A (ja) 補体関連蛋白質および炭水化物よりなる組成物、ならびに該組成物の製法および使用方法
LT4225B (en) Immuno-stimulatory monoclonal antibodies
HU218904B (hu) Eljárás ICAM-1-et kódoló rekombináns DNS előállítására, ICAM-1-et kifejező sejtek vagy ezzel kapcsolatos betegségek diagnosztizálására és a specifikus védekező rendszer válaszából eredő gyulladások kezelésére szolgáló gyógyszerkészítmények előállítására
US5587460A (en) 14-beta-gal mammalian lectins
JPH07505609A (ja) Ｃｄ８結合ドメイン・ペプチド
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
CA2347734A1 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
US7361351B1 (en) Method for sensitizing bovine mammary cells to respond to LPS
Wester et al. Carbohydrate groups of α1-microglobulin are important for secretion and tissue localization but not for immunological properties
WO1994011497A1 (fr) Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60
CA2374681C (fr) Nouvelle utilisation therapeuthique de la proteine modulatrice de l'inflammation virale pour bloquer le rejet d'une xenogreffe
WO1998008535A2 (fr) Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60
EP0303463B1 (fr) Méthode pour contrôler l'extravasation des leucocytes
HU217792B (hu) Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
US6406679B1 (en) Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells
EP0254647A2 (fr) Médicaments pour le traitement de maladies auto-immunes
Deuel et al. Platelet-derived growth factor. Structure, function, and roles in normal and transformed cells.
US20040096450A1 (en) Methods and compositions for treating diseases associated with increased Fas-ligand titers
WO2004096843A1 (fr) Polypeptide favorisant l'absorption par le systeme digestif
US20030129190A1 (en) FX activity in cells in cancer, inflammatory responses and diseases and in autoimmunity
US20090054330A1 (en) Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511850

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA